Registro PONTE-SC/SCA: ottimizzazione della terapia medica negli ambulatori pugliesi per i pazienti con scompenso cardiaco

View at publisher Summarise with VIRAT
Authors: Massimo Iacoviello, Gaetano Citarelli, Gianpaolo Palmieri, Pietro Scicchitano, Luisa De Gennaro, Francesco Massari, Massimo Vincenzo Bonfantino, Michele Accogli, Francesco Bartolomucci, Natale Daniele Brunetti, Cosimo Campanella, Marco Matteo Ciccone
+18 more Giuseppe Colonna, Paolo Colonna, G Dalena, Cosimo Angelo Greco, Giovanni Luzzi, Claudio Paolillo, Andrea Passantino, Giancarlo Piccinni, Ennio Pisanò, Domenico Rosario Potenza, Vito Sollazzo, Federico Nardi, Furio Colivicchi, Fabrizio Giovanni Oliva, Domenico Gabrielli, Massimo Grimaldi, Pasquale Caldarola, a nome degli Sperimentatori del Progetto PONTE-SC (in Append
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Despite advances in therapy, heart failure (HF) remains a syndrome characterized by high morbidity and mortality. The PONTE-HF/ACS registry aims to assess the outcomes of a structured outpatient follow-up between hospital and community care for patients with HF or recently hospitalized for acute coronary syndrome. The purpose of this study is to evaluate one of the main process indicators of the registry for patients with HF, namely the prescribed pharmacological therapy, with particular reference to therapy with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) or angiotensin receptor-neprilysin inhibitors (ARNi), beta-blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter 2 inhibitors (SGLT2i). METHODS: Between January 2024 and September 2025, 1203 patients were enrolled: 496 with HF and reduced ejection fraction (HFrEF), 189 with HF and mildly reduced ejection fraction (HFmrEF), 302 with HF and preserved ejection fraction (HFpEF), and 216 with HF and improved ejection fraction. RESULTS: In HFrEF patients, after enrollment, therapy was prescribed as follows: ACEi/ARB/ARNi in 89% of cases (64% ARNi), beta-blockers in 97%, MRA in 85%, and SGLT2i in 85%. Quadruple therapy with and without ARNi was prescribed in 69% and 51% of cases, respectively. The percentage of patients receiving at least 50% of the recommended dose was 63% for ARNi, 41% for ACEi/ARB, 70% for beta-blockers, and 98% for MRA. CONCLUSIONS: The PONTE-HF/ACS registry shows good optimization of therapy in enrolled patients with HFrEF. Achieving this important process indicator highlights the quality of care provided by the HF outpatient network in the Apulia region and confirms the relevance of the registry for the analysis and optimization of diagnostic-therapeutic pathways in patients with HF.

Fields of Study & Subjects

Heart Failure Treatment and Management Heart rate and cardiovascular health Cardiovascular Function and Risk Factors

Publication details

Journal / source
Giornale italiano di cardiologia
Volume
27
Issue
4
Pages
276–286
Publication date
25 March 2026
Language
IT